Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of ...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and ...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...

China is a beacon of global embryo research, says scientist on return from US to lead lab

Leading life scientist Wu Jun, who recently left the United States to return to his homeland, believes many of the world’s ...
Market.us Media

DNA Methylation Market Projected to Expand at a CAGR of 15.1% Through 2034

Global DNA Methylation Market size is expected to be worth around US$ 6.5 Billion by 2034 from US$ 1.6 Billion in 2024.
Science

An innovative colon inflammation-targeting platform for ulcerative colitis treatment

The therapeutic options for patients with inflammatory bowel disease (IBD) have recently expanded substantially. Tofacitinib, ...